MS-II-124
Based on 1 Customer Validation
MS-II-124 is an effective and selective NLRP3 inhibitor (IC50=0.12 μM) with anti-inflammatory and immunomodulatory activities, which can be used in the research of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS).
For research use only. We do not sell to patients.
- Purity : 99.66%
- CAS No.: 3037332-85-4
- Formula: C28H28ClFN2O4S
- Molecular Weight:543.05
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
IC50=0.12 μM (NLRP3)[1].
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ALI/ARDS WT C57BL/6 mice model[1].
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection (i.p.), Single dose. 1 h before i.n. instillation of LPS (40 μg in 40 μL PBS).
-
Result:Significantly inhibited lipopolysaccharide (LPS)-induced IL-1β production in pulmonary bronchoalveolar lavage fluid (BALF), whereas NLRP3 deletion did not significantly inhibit its production.
Chemical Information
-
CAS No. 3037332-85-4
-
Appearance Solid
-
Molecular Weight 543.05
-
Formula C28H28ClFN2O4S
-
Color White to off-white
-
SMILES
ClC1=CC=C(OCCC)C(CN(CCC2=CC=C(S(=O)(NCC#C)=O)C=C2)C(C3=CC=C(F)C=C3)=O)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 35 mg/mL (64.45 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Inhalation Toxicity Study
Inhalation toxicity studies expose rodents to a controlled aerosol, vapor, gas, or smoke atmosphere and assess respiratory and systemic toxicity using exposure-atmosphere characterization, clinical observations, body and organ weights, bronchoalveolar lavage fluid, histopathology, blood chemistry, hematology, and, when included, molecular endpoints such as transcriptomics, proteomics, lipidomics, or tissue burden analysis. The primary biological readouts are airway irritation, pulmonary inflammation, cytotoxicity, altered surfactant or lipid homeostasis, impaired particle clearance, and tissue remodeling, reflected by BALF cell differentials, BALF protein, LDH, phosphatase activities, cytokines, lung weight, microscopic respiratory-tract lesions, and retained lung burden.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8415 mL | 9.2073 mL | 18.4145 mL | 46.0363 mL |
| 5 mM | 0.3683 mL | 1.8415 mL | 3.6829 mL | 9.2073 mL | |
| 10 mM | 0.1841 mL | 0.9207 mL | 1.8415 mL | 4.6036 mL | |
| 15 mM | 0.1228 mL | 0.6138 mL | 1.2276 mL | 3.0691 mL | |
| 20 mM | 0.0921 mL | 0.4604 mL | 0.9207 mL | 2.3018 mL | |
| 25 mM | 0.0737 mL | 0.3683 mL | 0.7366 mL | 1.8415 mL | |
| 30 mM | 0.0614 mL | 0.3069 mL | 0.6138 mL | 1.5345 mL | |
| 40 mM | 0.0460 mL | 0.2302 mL | 0.4604 mL | 1.1509 mL | |
| 50 mM | 0.0368 mL | 0.1841 mL | 0.3683 mL | 0.9207 mL | |
| 60 mM | 0.0307 mL | 0.1535 mL | 0.3069 mL | 0.7673 mL |